<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJBM</journal-id><journal-title-group><journal-title>Hans Journal of Biomedicine</journal-title></journal-title-group><issn pub-type="epub">2161-8976</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJBM.2021.114026</article-id><article-id pub-id-type="publisher-id">HJBM-44947</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJBM20210400000_74938704.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  基于网络药理学和分子对接技术分析茵陈治疗肝癌的潜在作用机制
  Analysis of the Potential Mechanism of Artemisiae Scopariae Herba in the Treatment of Liver Cancer based on Network Pharmacology and Molecular Docking Technology
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>文花</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>鲁红</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>山西师范大学现代文理学院，山西 临汾；山西师范大学生命科学学院，山西 临汾</addr-line></aff><aff id="aff3"><addr-line>山西师范大学现代文理学院，山西 临汾</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>30</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>04</issue><fpage>201</fpage><lpage>213</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：运用网络药理学和分子对接技术阐释茵陈抗肝癌的作用机制。方法：用TCMSP和UniProt数据库收集茵陈的活性成分并预测其潜在靶点。通过GeneCards、OMIM、TTD数据库筛选肝癌相关靶点。用在线软件Draw Venn Diagram将药物和疾病靶点取交集，将交集靶点导入DAVID 6.8在线数据库进行GO和KEGG分析。通过STRING数据库构建靶蛋白互作网络，用Cytoscape软件筛选关键基因，并用AutoDock Vina软件对关键靶点进行分子对接分析。结果：茵陈共筛选出13个活性成分，药物和疾病交集靶点103个，最终筛选出CDKN1A、CDK2、JUN、E2F1、RB1、TNF、IL6、CCNA2、IL1B、CXCL8 10个关键靶点，关键靶点与部分活性成分对接较好。结论：茵陈中的活性成分通过作用于CDKN1A、CDK2、CXCL8等靶点，参与调控细胞周期、机体的炎症反应以及癌症等信号通路，从而可能发挥对肝癌的治疗作用。
   Objective: The network pharmacology and molecular docking technology were used to elucidate the mechanism of Artemisiae Scopariae Herba (ASH) against liver cancer. Methods: TCMSP and UniProt databases were used to collect the active components of ASH and predict their potential targets. The target of liver cancer was screened by GeneCards, OMIM and TTD database. The intersection of drug and disease targets was obtained by online software Draw Venn Diagram, and the intersection tar-gets were imported into David 6.8 for GO and KEGG function enrichment analysis. Construction of protein-protein interaction network through STRING database, Cytoscape software was used to screen hub genes. Molecular docking analysis of hub genes was carried out with AutoDock Vina software. Results: A total of 13 active components were screened out from ASH and 103 drug and disease intersection targets were screened. Finally, 10 hub targets including CDKN1A, CDK2, JUN, E2F1, RB1, TNF, IL6, CCNA2, IL1B and CXCL8 were screened out. The hub targets were docked well with some active components. Conclusion: The active components of ASH are involved in regulating cell cycle, inflammatory response, cancer and other signaling pathways by acting on CDKN1A, CDK2, CXCL8 and other targets, which may play a role in the treatment of liver cancer.
 
</p></abstract><kwd-group><kwd>茵陈，肝癌，网络药理学，分子对接, Artemisiae Scopariae Herba</kwd><kwd> Liver Cancer</kwd><kwd> Network Pharmacology</kwd><kwd> Molecular Docking</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：运用网络药理学和分子对接技术阐释茵陈抗肝癌的作用机制。方法：用TCMSP和UniProt数据库收集茵陈的活性成分并预测其潜在靶点。通过GeneCards、OMIM、TTD数据库筛选肝癌相关靶点。用在线软件Draw Venn Diagram将药物和疾病靶点取交集，将交集靶点导入DAVID 6.8在线数据库进行GO和KEGG分析。通过STRING数据库构建靶蛋白互作网络，用Cytoscape软件筛选关键基因，并用AutoDock Vina软件对关键靶点进行分子对接分析。结果：茵陈共筛选出13个活性成分，药物和疾病交集靶点103个，最终筛选出CDKN1A、CDK2、JUN、E2F1、RB1、TNF、IL6、CCNA2、IL1B、CXCL8 10个关键靶点，关键靶点与部分活性成分对接较好。结论：茵陈中的活性成分通过作用于CDKN1A、CDK2、CXCL8等靶点，参与调控细胞周期、机体的炎症反应以及癌症等信号通路，从而可能发挥对肝癌的治疗作用。</p></sec><sec id="s2"><title>关键词</title><p>茵陈，肝癌，网络药理学，分子对接</p></sec><sec id="s3"><title>Analysis of the Potential Mechanism of Artemisiae Scopariae Herba in the Treatment of Liver Cancer based on Network Pharmacology and Molecular Docking Technology<sup> </sup></title><p>Wenhua Guo<sup>1,2</sup>, Luhong Yang<sup>1</sup></p><p><sup>1</sup>Modern College of Humanities and Science of Shanxi Normal University, Linfen Shanxi</p><p><sup>2</sup>School of Life Science, Shanxi Normal University, Linfen Shanxi</p><p><img src="//html.hanspub.org/file/3-1530184x4_hanspub.png?20210901165708463" /></p><p>Received: Jul. 23<sup>rd</sup>, 2021; accepted: Aug. 13<sup>th</sup>, 2021; published: Sep. 1<sup>st</sup>, 2021</p><p><img src="//html.hanspub.org/file/3-1530184x5_hanspub.png?20210901165708463" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: The network pharmacology and molecular docking technology were used to elucidate the mechanism of Artemisiae Scopariae Herba (ASH) against liver cancer. Methods: TCMSP and UniProt databases were used to collect the active components of ASH and predict their potential targets. The target of liver cancer was screened by GeneCards, OMIM and TTD database. The intersection of drug and disease targets was obtained by online software Draw Venn Diagram, and the intersection targets were imported into David 6.8 for GO and KEGG function enrichment analysis. Construction of protein-protein interaction network through STRING database, Cytoscape software was used to screen hub genes. Molecular docking analysis of hub genes was carried out with AutoDock Vina software. Results: A total of 13 active components were screened out from ASH and 103 drug and disease intersection targets were screened. Finally, 10 hub targets including CDKN1A, CDK2, JUN, E2F1, RB1, TNF, IL6, CCNA2, IL1B and CXCL8 were screened out. The hub targets were docked well with some active components. Conclusion: The active components of ASH are involved in regulating cell cycle, inflammatory response, cancer and other signaling pathways by acting on CDKN1A, CDK2, CXCL8 and other targets, which may play a role in the treatment of liver cancer.</p><p>Keywords:Artemisiae Scopariae Herba, Liver Cancer, Network Pharmacology, Molecular Docking</p><disp-formula id="hanspub.44947-formula15"><graphic xlink:href="//html.hanspub.org/file/3-1530184x6_hanspub.png?20210901165708463"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-1530184x7_hanspub.png?20210901165708463" /> <img src="//html.hanspub.org/file/3-1530184x8_hanspub.png?20210901165708463" /></p></sec><sec id="s5"><title>1. 引言</title><p>肝癌在世界最常见的癌症中排名第五，是导致癌症死亡的第三大原因，缺乏合适的早期发现的生物标志物和有限的治疗策略是高死亡率的主要原因 [<xref ref-type="bibr" rid="hanspub.44947-ref1">1</xref>]。肝细胞癌(HCC)是肝癌最常见的形式，占肝癌的90%，是男性癌症相关死亡的第二大原因，在女性中是第六大原因 [<xref ref-type="bibr" rid="hanspub.44947-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.44947-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.44947-ref4">4</xref>]。肝炎病毒，肥胖，饮食习惯，脂肪肝疾病，肝硬化等是与肝癌相关的危险因素 [<xref ref-type="bibr" rid="hanspub.44947-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.44947-ref6">6</xref>]。乙型和丙型肝炎病毒可引起急性和慢性感染，导致肝癌 [<xref ref-type="bibr" rid="hanspub.44947-ref7">7</xref>]。神经系统相关因子在肝癌中参与调控癌细胞的迁移、增殖和凋亡，并在治疗后的侵袭、转移和复发中发挥调节作用 [<xref ref-type="bibr" rid="hanspub.44947-ref8">8</xref>]。外泌体在多种肝脏疾病中发挥重要的作用，如病毒性肝炎、酒精性肝病、脂肪肝等，甚至参与肝纤维化的进展，最终参与肝癌的发生发展 [<xref ref-type="bibr" rid="hanspub.44947-ref9">9</xref>]。肝纤维化与肝癌死亡风险显著增加有关 [<xref ref-type="bibr" rid="hanspub.44947-ref10">10</xref>]。肿瘤微环境可影响癌细胞的存活、信号转导和转移，肝癌微环境包括与癌相关的成纤维细胞(CAFs)、肝星状细胞(HSCs)、内皮细胞、免疫细胞、生长因子、炎性细胞因子和细胞外基质蛋白 [<xref ref-type="bibr" rid="hanspub.44947-ref11">11</xref>]。</p><p>茵陈(Artemisiae Scopariae Herba) 也叫茵陈蒿，为菊科植物滨蒿(Artemisia scoparia Waldst. et Kit.)或茵陈蒿(Artemisia capillaris Thunb.)的地上干燥部分 [<xref ref-type="bibr" rid="hanspub.44947-ref12">12</xref>]。茵陈蒿作为传统药物广泛用于治疗肝炎、肝脏胆汁淤积、黄疸、胆囊功能障碍和消化系统疾病，对慢性乙型肝炎病毒感染和肝硬化具有抗炎作用，其主要成分如卡青霉素和东莨菪酮对乳腺癌、前列腺癌、肺癌和肝癌均有抗肿瘤作用 [<xref ref-type="bibr" rid="hanspub.44947-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.44947-ref14">14</xref>]。研究发现茵陈干叶中的一种提取物比茵陈全株具有更强的抗癌活性，通过抑制PI3K/AKT通路抑制细胞生长并诱导线粒体介导的细胞凋亡，而PI3K/AKT通路上调与HCC预后不良有关 [<xref ref-type="bibr" rid="hanspub.44947-ref13">13</xref>]。茵陈提取物对肝炎具有一定的治疗效果，还能抑制肝癌细胞的生长、侵袭和转移，诱导细胞凋亡，起到肝保护的作用 [<xref ref-type="bibr" rid="hanspub.44947-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.44947-ref16">16</xref>]。</p><p>肝癌目前的治疗方案有手术治疗、局部消融、经肝动脉化疗栓塞术、放射治疗、药物治疗和免疫疗法等，但它们都有各自的缺点 [<xref ref-type="bibr" rid="hanspub.44947-ref17">17</xref>]。中医药在肝癌的治疗和预防方面都起到一定作用，包括抑制肿瘤生长、抗转移、抗炎症、诱导/降低氧化应激 [<xref ref-type="bibr" rid="hanspub.44947-ref18">18</xref>]。茵陈作为一种传统中药，具有一定的肝保护功能，有望对肝癌起到一定的治疗效果。</p></sec><sec id="s6"><title>2. 方法</title><sec id="s6_1"><title>2.1. 茵陈的活性成分和作用靶点的筛选</title><p>TCMSP数据库(https://tcmspw.com/tcmsp.php)中以“茵陈”为关键词检索其全部化学成分，活性成分的筛选条件设置为药物口服利用度(OB) ≥ 30%，类药性(DL) ≥ 0.18。活性成分的作用靶标在TCMSP数据库查询，将得到的靶标蛋白在UniProt(https://www.uniprot.org/)数据库中进行规范，获得靶蛋白对应的基因名。</p></sec><sec id="s6_2"><title>2.2. 肝癌疾病靶点的获取</title><p>在GeneCards (https://www.genecards.org/)，OMIM (https://omim.org/)，TTD (http://db.idrblab.net/ttd/)数据库中输入关键词“liver cancer”，检索肝癌相关靶点，整合三个数据库的结果并去除重复。</p></sec><sec id="s6_3"><title>2.3. 交集基因的获取</title><p>通过Draw Venn Diagram (http://bioinformatics.psb.ugent.be/webtools/Venn/)将茵陈活性成分的靶点与肝癌靶点取交集，获得茵陈治疗肝癌的作用靶点，用Cytoscape软件构建茵陈与肝癌的“药物–成分–疾病–靶点”网络图。</p></sec><sec id="s6_4"><title>2.4. GO和KEGG分析</title><p>通过DAVID 6.8在线数据库(https://david.ncifcrf.gov/)对交集基因做GO和KEGG富集分析，设定物种为人，并用R软件对结果做可视化处理。</p></sec><sec id="s6_5"><title>2.5. PPI网络构建和关键基因获取</title><p>将交集基因导入STRING在线数据库(https://string-db.org/)，物种选择“Homo sapiens”，构建蛋白互作网络。下载蛋白互作网络结果的TSV 格式文本并导入Cytoscape软件，用cytoHubba插件筛选排名前10位的关键基因。</p></sec><sec id="s6_6"><title>2.6. 分子对接</title><p>用关键基因(受体)与各自在“药物–成分–疾病–靶点”网络中对应的茵陈成分(配体)进行分子对接。在PDB数据库(https://www.rcsb.org/)下载靶点蛋白的结构，PyMOL软件去除溶剂分子和小分子配体，用AutoDock软件进行加氢等操作。从PubChem数据库(https://pubchem.ncbi.nlm.nih.gov/)中下载化合物2D结构，用ChemOffice软件构建3D结构并进行优化。用Vina软件对转化为*pdbqt格式的分子和靶点进行对接，结合能 ≤ −5.0 kJ&#183;mol<sup>−1</sup>表明分子与靶点对接较好。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 茵陈活性成分及作用靶点</title><p>茵陈活性成分共获得13种(表1)，在TCMSP数据库种查找它们对应的靶点并在UniProt数据库中进行注释和校正，删除重复和没有查到对应基因名的靶点，共获得169个单一靶点。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Active components of Artemisiae Scopariae Herba (ASH</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Mol ID</th><th align="center" valign="middle" >Molecule Name</th><th align="center" valign="middle" >OB (%)</th><th align="center" valign="middle" >DL</th></tr></thead><tr><td align="center" valign="middle" >MOL008045</td><td align="center" valign="middle" >4’-Methylcapillarisin</td><td align="center" valign="middle" >72.18</td><td align="center" valign="middle" >0.35</td></tr><tr><td align="center" valign="middle" >MOL008047</td><td align="center" valign="middle" >Artepillin A</td><td align="center" valign="middle" >68.32</td><td align="center" valign="middle" >0.24</td></tr><tr><td align="center" valign="middle" >MOL008043</td><td align="center" valign="middle" >Capillarisin</td><td align="center" valign="middle" >57.56</td><td align="center" valign="middle" >0.31</td></tr><tr><td align="center" valign="middle" >MOL008039</td><td align="center" valign="middle" >Isoarcapillin</td><td align="center" valign="middle" >57.4</td><td align="center" valign="middle" >0.41</td></tr><tr><td align="center" valign="middle" >MOL008046</td><td align="center" valign="middle" >Demethoxycapillarisin</td><td align="center" valign="middle" >52.33</td><td align="center" valign="middle" >0.25</td></tr><tr><td align="center" valign="middle" >MOL000354</td><td align="center" valign="middle" >Isorhamnetin</td><td align="center" valign="middle" >49.6</td><td align="center" valign="middle" >0.31</td></tr><tr><td align="center" valign="middle" >MOL004609</td><td align="center" valign="middle" >Areapillin</td><td align="center" valign="middle" >48.96</td><td align="center" valign="middle" >0.41</td></tr><tr><td align="center" valign="middle" >MOL000098</td><td align="center" valign="middle" >Quercetin</td><td align="center" valign="middle" >46.43</td><td align="center" valign="middle" >0.28</td></tr><tr><td align="center" valign="middle" >MOL008040</td><td align="center" valign="middle" >Eupalitin</td><td align="center" valign="middle" >46.11</td><td align="center" valign="middle" >0.33</td></tr><tr><td align="center" valign="middle" >MOL008041</td><td align="center" valign="middle" >Eupatolitin</td><td align="center" valign="middle" >42.55</td><td align="center" valign="middle" >0.37</td></tr><tr><td align="center" valign="middle" >MOL005573</td><td align="center" valign="middle" >Genkwanin</td><td align="center" valign="middle" >37.13</td><td align="center" valign="middle" >0.24</td></tr><tr><td align="center" valign="middle" >MOL000358</td><td align="center" valign="middle" >Beta-sitosterol</td><td align="center" valign="middle" >36.91</td><td align="center" valign="middle" >0.75</td></tr><tr><td align="center" valign="middle" >MOL007274</td><td align="center" valign="middle" >Skrofulein</td><td align="center" valign="middle" >30.35</td><td align="center" valign="middle" >0.3</td></tr></tbody></table></table-wrap><p>表1. 茵陈有效成分</p></sec><sec id="s7_2"><title>3.2. 肝癌相关靶点</title><p>在Genecards数据库获得肝癌相关基因16,489个，以relevance score &gt; 20筛选得到1004个基因。在OMIM数据库中得到493个靶点，TTD数据库获得13个靶点，将三个数据库的靶点合并删除重复后剩余1410个与肝癌相关的基因靶点。</p></sec><sec id="s7_3"><title>3.3. 药物与疾病的交集靶点</title><p>在Draw Venn Diagram中获得茵陈与肝癌的交集靶点103个(图1)，将交集靶点导入Cytoscape软件构建“药物–成分–疾病–靶点”网络，其中红色代表茵陈，紫色代表肝癌，黄色代表茵陈活性成分，绿色代表靶点(图2)。</p><p>图1. 肝癌和茵陈的交集基因</p><p>图2. “药物–成分–疾病–靶点”网络</p></sec><sec id="s7_4"><title>3.4. GO和KEGG富集分析</title><p>用DAVID6.8对茵陈治疗肝癌的靶点做富集分析，设置P &lt; 0.01和FDR &lt; 0.01为界限，共获得GO条目229条，KEGG条目92条。根据P值进行排序，用R软件分别对GO条目前30和KEGG条目前20做可视化分析(表2、表3、图3、图4)。</p><p>GO可视化分析显示交集靶点主要富集在生物过程(BP)中，涉及对血管生成，炎症反应，基因表达，转录，细胞增殖与凋亡等过程的调控，以及对一些化合物和特殊环境的应答反应。</p><p>KEGG可视化分析显示交集靶点涉及癌症通路，膀胱癌、前列腺癌、胰腺癌、小细胞肺癌等癌症，乙型和丙型肝炎，TNF、HIF-1、p53信号通路，Toll样受体信号通路等。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> GO enrichment analysi</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >GO-term</th><th align="center" valign="middle" >Gene counts</th><th align="center" valign="middle" >P-value</th></tr></thead><tr><td align="center" valign="middle" >enzyme binding</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >1.43E−24</td></tr><tr><td align="center" valign="middle" >positive regulation of transcription from RNA polymerase II promoter</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >2.19E−19</td></tr><tr><td align="center" valign="middle" >response to drug</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >6.69E−18</td></tr><tr><td align="center" valign="middle" >negative regulation of apoptotic process</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >1.99E−17</td></tr><tr><td align="center" valign="middle" >positive regulation of transcription, DNA-templated</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" >3.21E−17</td></tr><tr><td align="center" valign="middle" >identical protein binding</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >3.33E−15</td></tr><tr><td align="center" valign="middle" >protein binding</td><td align="center" valign="middle" >91</td><td align="center" valign="middle" >5.82E−15</td></tr><tr><td align="center" valign="middle" >cellular response to hypoxia</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >1.85E−14</td></tr><tr><td align="center" valign="middle" >extracellular space</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >2.19E−14</td></tr><tr><td align="center" valign="middle" >positive regulation of gene expression</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >2.36E−14</td></tr><tr><td align="center" valign="middle" >transcription factor binding</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >8.67E−14</td></tr><tr><td align="center" valign="middle" >extrinsic apoptotic signaling pathway in absence of ligand</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >3.63E−13</td></tr><tr><td align="center" valign="middle" >angiogenesis</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >3.77E−13</td></tr><tr><td align="center" valign="middle" >cellular response to organic cyclic compound</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >2.14E−12</td></tr><tr><td align="center" valign="middle" >response to toxic substance</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >3.52E−12</td></tr><tr><td align="center" valign="middle" >positive regulation of nitric oxide biosynthetic process</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >3.73E−12</td></tr><tr><td align="center" valign="middle" >cellular response to lipopolysaccharide</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >3.87E−12</td></tr><tr><td align="center" valign="middle" >positive regulation of angiogenesis</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >4.78E−12</td></tr><tr><td align="center" valign="middle" >response to estradiol</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >7.57E−12</td></tr><tr><td align="center" valign="middle" >aging</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >2.17E−11</td></tr></tbody></table></table-wrap><p>表2. GO富集分析</p><p>图3. GO富集分析柱状图</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Enrichment analysis of KEGG pathwa</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Pathway</th><th align="center" valign="middle" >Gene counts</th><th align="center" valign="middle" >P-value</th></tr></thead><tr><td align="center" valign="middle" >Pathways in cancer</td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >9.82E−30</td></tr><tr><td align="center" valign="middle" >Hepatitis B</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >6.98E−28</td></tr><tr><td align="center" valign="middle" >Bladder cancer</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >9.06E−22</td></tr><tr><td align="center" valign="middle" >Prostate cancer</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >6.38E−21</td></tr><tr><td align="center" valign="middle" >Pancreatic cancer</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >8.42E−18</td></tr><tr><td align="center" valign="middle" >Small cell lung cancer</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >5.11E−17</td></tr><tr><td align="center" valign="middle" >Chagas disease (American trypanosomiasis)</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >1.20E−16</td></tr><tr><td align="center" valign="middle" >TNF signaling pathway</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >2.10E−16</td></tr><tr><td align="center" valign="middle" >HIF-1 signaling pathway</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >5.10E−16</td></tr><tr><td align="center" valign="middle" >Non-small cell lung cancer</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >5.57E−16</td></tr><tr><td align="center" valign="middle" >Influenza A</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >1.65E−14</td></tr><tr><td align="center" valign="middle" >Proteoglycans in cancer</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >2.55E−14</td></tr><tr><td align="center" valign="middle" >Colorectal cancer</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >7.84E−14</td></tr><tr><td align="center" valign="middle" >Toxoplasmosis</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >1.09E−13</td></tr><tr><td align="center" valign="middle" >Hepatitis C</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >2.06E−13</td></tr><tr><td align="center" valign="middle" >p53 signaling pathway</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >2.49E−13</td></tr><tr><td align="center" valign="middle" >Chronic myeloid leukemia</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >7.18E−13</td></tr><tr><td align="center" valign="middle" >Toll-like receptor signaling pathway</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >9.02E−13</td></tr><tr><td align="center" valign="middle" >Glioma</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >3.44E−12</td></tr><tr><td align="center" valign="middle" >HTLV-I infection</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >3.57E−12</td></tr></tbody></table></table-wrap><p>表3. KEGG通路富集分析</p><p>图4. KEGG分析气泡图</p></sec><sec id="s7_5"><title>3.5. PPI网络和关键基因</title><p>将茵陈治疗肝癌的靶点导入STRING，设定置信度高于0.95并删除没有联系的靶点，得到蛋白互作网络(图5)。将TSV格式文本导入Cytoscape软件，用 cytoHubba插件根据MCC算法筛选10个关键基因，分别为CDKN1A、CDK2、JUN、E2F1、RB1、TNF、IL6、CCNA2、IL1B、CXCL8 (图6)。</p></sec><sec id="s7_6"><title>3.6. 分子对接结果</title><p>选取PPI网络中排名前10位的核心基因与它们在“药物–成分–疾病–靶点”网络中对应的成分进行分子对接，结果显示靶点与其对应的成分均对接良好，其中JUN与槲皮素对接最好(表4)。槲皮素与JUN活性位点ARG-270、LYS-273、LEU-274形成疏水相互作用，与SER-269、ARG-270形成氢键，与ARG-270形成π-阳离子相互作用(图7)。</p><p>图5. PPI网络</p><p>图6. 关键基因</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Molecular dockin</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >靶点</th><th align="center" valign="middle" >成分</th><th align="center" valign="middle" >结合能/kJ&#183;mol<sup>−</sup><sup>1</sup></th></tr></thead><tr><td align="center" valign="middle" >CDKN1A</td><td align="center" valign="middle" >quercetin</td><td align="center" valign="middle" >−5.7</td></tr><tr><td align="center" valign="middle" >CDK2</td><td align="center" valign="middle" >isorhamnetin</td><td align="center" valign="middle" >−7.6</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Eupalitin</td><td align="center" valign="middle" >−7.2</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Eupatolitin</td><td align="center" valign="middle" >−7.7</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >capillarisin</td><td align="center" valign="middle" >−7.0</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >4'-Methylcapillarisin</td><td align="center" valign="middle" >−7.5</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Demethoxycapillarisin</td><td align="center" valign="middle" >−7.7</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Artepillin A</td><td align="center" valign="middle" >−6.9</td></tr><tr><td align="center" valign="middle" >JUN</td><td align="center" valign="middle" >beta-sitosterol</td><td align="center" valign="middle" >−7.3</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >quercetin</td><td align="center" valign="middle" >−9.4</td></tr><tr><td align="center" valign="middle" >E2F1</td><td align="center" valign="middle" >quercetin</td><td align="center" valign="middle" >−8.4</td></tr><tr><td align="center" valign="middle" >RB1</td><td align="center" valign="middle" >quercetin</td><td align="center" valign="middle" >−8.2</td></tr><tr><td align="center" valign="middle" >TNF</td><td align="center" valign="middle" >quercetin</td><td align="center" valign="middle" >−8.7</td></tr><tr><td align="center" valign="middle" >IL6</td><td align="center" valign="middle" >quercetin</td><td align="center" valign="middle" >−7.8</td></tr><tr><td align="center" valign="middle" >CCNA2</td><td align="center" valign="middle" >isorhamnetin</td><td align="center" valign="middle" >−7.7</td></tr><tr><td align="center" valign="middle" >IL1B</td><td align="center" valign="middle" >quercetin</td><td align="center" valign="middle" >−8.0</td></tr><tr><td align="center" valign="middle" >CXCL8</td><td align="center" valign="middle" >quercetin</td><td align="center" valign="middle" >−6.8</td></tr></tbody></table></table-wrap><p>表4. 分子对接</p><p>图7. 槲皮素与JUN分子对接</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>本研究中，我们共获得茵陈的13种有效成分，它们属于黄酮类、色原酮类和植物甾醇类化合物。黄酮类化合物可以调节几乎所有参与癌变的关键过程，包括细胞凋亡、增殖、血管生成和转移进展，触发细胞周期阻滞，促进肿瘤抑制基因的表达 [<xref ref-type="bibr" rid="hanspub.44947-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.44947-ref20">20</xref>]。此外，黄酮类化合物还具有抗菌、抗病毒特性，对人工诱导的肝损伤具有潜在的保护作用 [<xref ref-type="bibr" rid="hanspub.44947-ref20">20</xref>]。色原酮类化合物具有抗菌、抗氧化、抗病毒、抗肿瘤活性，对炎症性疾病、癌症、神经退行性疾病、传染病等疾病都起到一定的作用，对肝代谢酶也有作用 [<xref ref-type="bibr" rid="hanspub.44947-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.44947-ref22">22</xref>]。植物甾醇可以影响宿主系统，通过提高对癌症的免疫应答识别来实现抗肿瘤反应，同时也表现出直接抑制肿瘤生长的特性，包括减少细胞周期进程、诱导细胞凋亡和抑制肿瘤转移 [<xref ref-type="bibr" rid="hanspub.44947-ref23">23</xref>]。植物甾醇的摄入还可以减少肝脏炎症，具有保肝的作用 [<xref ref-type="bibr" rid="hanspub.44947-ref24">24</xref>]。</p><p>PPI网络显示茵陈抗肝癌的作用靶点并非单独起作用，而是一个复杂的网络，根据PPI结果最终筛选出10个关键基因，分别为CDKN1A、CDK2、JUN、E2F1、RB1、TNF、IL6、CCNA2、IL1B、CXCL8。CDKN1A别名 P21，可以促进细胞周期阻滞，在阻止细胞增殖中起重要作用 [<xref ref-type="bibr" rid="hanspub.44947-ref25">25</xref>]。研究表明，p21既可以作为致癌基因，也可以作为肿瘤抑制因子，作为肿瘤抑制因子的作用依赖于NF-kB，此外p21还对DNA损伤具有保护作用 [<xref ref-type="bibr" rid="hanspub.44947-ref26">26</xref>]。CDK2在细胞分化和凋亡中发挥关键作用，经常在人类肿瘤中过度表达，而大多数正常组织低表达，有药理证据表明CDK2过表达导致细胞周期调控异常，与癌细胞的过度增殖直接相关 [<xref ref-type="bibr" rid="hanspub.44947-ref27">27</xref>] [<xref ref-type="bibr" rid="hanspub.44947-ref28">28</xref>]。CDK2 mRNA在原发性肝细胞癌组织中表达显著增加，在肝癌细胞的侵袭和转移中发挥作用 [<xref ref-type="bibr" rid="hanspub.44947-ref29">29</xref>]。</p><p>JUN基因编码核内重要的癌蛋白，Jun 家族主要有Jun B、c-Jun、Jun D 3类，在原发性肝细胞癌组织中，核内转录基因Jun D表达产物的表达强度明显增高 [<xref ref-type="bibr" rid="hanspub.44947-ref30">30</xref>]。转录激活因子E2F1参与细胞周期调控、凋亡、衰老、DNA损伤反应等多种细胞信号通路和生物学过程，通过影响多种信号通路调控多种癌症进展 [<xref ref-type="bibr" rid="hanspub.44947-ref31">31</xref>]。晚期肝癌患者的肿瘤中，E2F1基因剂量有轻微但显著的增加 [<xref ref-type="bibr" rid="hanspub.44947-ref32">32</xref>]。</p><p>肿瘤抑制基因RB1编码细胞周期的负调控因子，是多种类型癌症的肿瘤抑制因子，包括肝癌 [<xref ref-type="bibr" rid="hanspub.44947-ref33">33</xref>]。RB1在肝细胞癌中经常失活导致了肿瘤的多样性和染色体不稳定性，pRb蛋白在细胞周期调控中起着关键作用，尤其是在S-G2转化过程中，还调控参与细胞分化、凋亡、DNA损伤反应、衰老的几种下游通路 [<xref ref-type="bibr" rid="hanspub.44947-ref34">34</xref>]。TNF-α编码一种促炎细胞因子，在炎症性自身免疫性疾病和恶性疾病的发病机制中有一定作用，也被证实能促进肝癌的生长、侵袭和转移，并与肝癌患者的临床预后相关，TNF-α在肝脏修复和保护肝脏免受慢性损伤中发挥关键作用 [<xref ref-type="bibr" rid="hanspub.44947-ref35">35</xref>]。IL-6影响肝癌的增殖，并在肝癌的发生和复发中起重要作用，也可通过激活STAT3影响肝癌细胞的增殖、凋亡、侵袭和转移 [<xref ref-type="bibr" rid="hanspub.44947-ref36">36</xref>]。</p><p>细胞周期蛋白A2 (CCNA2)通过促进S期的进入和进展来调控细胞周期，在缺乏CCNA2的情况下，肿瘤细胞增殖受损 [<xref ref-type="bibr" rid="hanspub.44947-ref37">37</xref>] [<xref ref-type="bibr" rid="hanspub.44947-ref38">38</xref>]。IL-1B诱导大量生长因子和血管生成因子，促进肿瘤生长和转移，细菌或病毒感染在肝癌的致癌过程中起重要作用，血浆中IL1b的浓度在感染或炎症患者升高 [<xref ref-type="bibr" rid="hanspub.44947-ref39">39</xref>] [<xref ref-type="bibr" rid="hanspub.44947-ref40">40</xref>]。CXCL8改变了肝癌中miRNA的表达谱，促进肝癌细胞的转移和生存 [<xref ref-type="bibr" rid="hanspub.44947-ref11">11</xref>]。越来越多的研究表明CXCL8及其受体在多种类型的人类癌症中过表达，包括结直肠癌、前列腺癌、宫颈癌和非小细胞肺癌，在肝癌组织中高表达，与非肝癌组织相比，CXCL8的上调与临床分期和肿瘤浸润密切相关 [<xref ref-type="bibr" rid="hanspub.44947-ref41">41</xref>]。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，本研究以茵陈为研究对象，通过网络药理学和分子对接方法对茵陈治疗肝癌的有效成分、作用靶点、分子机制进行了初步预测，为今后肝癌的治疗提供了一定的理论指导。</p></sec><sec id="s10"><title>基金项目</title><p>山西师范大学现代文理学院基础研究基金项目(NO. 2020JCYJ19)。</p></sec><sec id="s11"><title>文章引用</title><p>郭文花,杨鲁红. 基于网络药理学和分子对接技术分析茵陈治疗肝癌的潜在作用机制Analysis of the Potential Mechanism of Artemisiae Scopariae Herba in the Treatment of Liver Cancer based on Network Pharmacology and Molecular Docking Technology[J]. 生物医学, 2021, 11(04): 201-213. https://doi.org/10.12677/HJBM.2021.114026</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44947-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Liu, M., Yan, Q., Sun, Y., Nam, Y., Hu, L., Loong, J.H.C., et al. (2020) A Hepatocyte Differentiation Model Reveals Two Subtypes of Liver Cancer with Different Oncofetal Properties and Therapeutic Targets. Proceedings of the National Academy of Sciences of the United States of America, 117, 6103-6113. &lt;br&gt;https://doi.org/10.1073/pnas.1912146117</mixed-citation></ref><ref id="hanspub.44947-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Shibata, T. and Aburatani, H. (2014) Exploration of Liver Cancer Genomes. Nature Reviews. Gastroenterology &amp; Hepatology, 11, 340-349. &lt;br&gt;https://doi.org/10.1038/nrgastro.2014.6</mixed-citation></ref><ref id="hanspub.44947-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Ali, E.S., Rychkov, G.Y. and Barritt, G.J. (2019) Deranged Hepatocyte Intracellular Ca2+ Homeostasis and the Progression of Non-Alcoholic Fatty Liver Disease to Hepatocellular Carcinoma. Cell calcium, 82, Article ID: 102057.  
&lt;br&gt;https://doi.org/10.1016/j.ceca.2019.102057</mixed-citation></ref><ref id="hanspub.44947-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, C.P., Wang, A.Q., Zhang, H.H., Wan, X.-S., Yang, X.-B., Zhao, H.-T., et al. (2015) Research Progress and Prospects of Markers for Liver Cancer Stem Cells. World Journal of Gastroenterology, 21, 12190-12196.  
&lt;br&gt;https://doi.org/10.3748/wjg.v21.i42.12190</mixed-citation></ref><ref id="hanspub.44947-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Anwanwan, D., Singh, S.K., Singh, S., Saikam, V. and Singh, R. (2020) Challenges in Liver Cancer and Possible Treatment Approaches. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1873, Article ID: 188314.  
&lt;br&gt;https://doi.org/10.1016/j.bbcan.2019.188314</mixed-citation></ref><ref id="hanspub.44947-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Yang, W.S., Zeng, X.F., Liu, Z.N., Zhao, Q.-H., Tan, Y.T., Gao, J., et al. (2020) Diet and Liver Cancer Risk: A Narrative Review of Epidemiological Evidence. The British Journal of Nutrition, 124, 330-340.  
&lt;br&gt;https://doi.org/10.1017/S0007114520001208</mixed-citation></ref><ref id="hanspub.44947-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Ringelhan, M., McKeating, J.A. and Protzer, U. (2017) Viral Hepatitis and Liver Cancer. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences, 372, Article ID: 20160274.  
&lt;br&gt;https://doi.org/10.1098/rstb.2016.0274</mixed-citation></ref><ref id="hanspub.44947-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Jeong, S., Zheng, B., Wang, H., Xia, Q. and Chen, L. (2018) Nervous System and Primary Liver Cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1869, 286-292. &lt;br&gt;https://doi.org/10.1016/j.bbcan.2018.04.002</mixed-citation></ref><ref id="hanspub.44947-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Wang, H., Lu, Z. and Zhao, X. (2019) Tumorigenesis, Diagnosis, and Therapeutic Potential of Exosomes in Liver Cancer. Journal of Hematology &amp; Oncology, 12, Article No. 133. &lt;br&gt;https://doi.org/10.1186/s13045-019-0806-6</mixed-citation></ref><ref id="hanspub.44947-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Sung, K.C., Johnston, M.P., Lee, M.Y. and Byrne, C.D. (2020) Non-Invasive Liver Fibrosis Scores Are Strongly Associated with Liver Cancer Mortality in General Population without Liver Disease. Liver International, 40, 1303-1315.  
&lt;br&gt;https://doi.org/10.1111/liv.14416</mixed-citation></ref><ref id="hanspub.44947-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Yin, Z., Huang, J., Ma, T., Li, D., Wu, Z., Hou, B., et al. (2017) Macrophages Activating Chemokine (C-X-C Motif) Ligand 8/miR-17 Cluster Modulate Hepatocellular Carcinoma Cell Growth and Metastasis. American Journal of Translational Research, 9, 2403-2411.</mixed-citation></ref><ref id="hanspub.44947-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">刘玉萍, 邱小玉, 刘烨, 马国. 茵陈的药理作用研究进展[J]. 中草药, 2019, 50(9): 2235-2241.</mixed-citation></ref><ref id="hanspub.44947-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Kim, J., Jung, K.H., Yan, H.H., Cheon, M.J., Kang, S., Jin, X., et al. (2018) Artemisia Capillaris Leaves Inhibit Cell Proliferation and Induce Apoptosis in Hepatocellular Carcinoma. BMC Complementary and Alternative Medicine, 18, Article No. 147. &lt;br&gt;https://doi.org/10.1186/s12906-018-2217-6</mixed-citation></ref><ref id="hanspub.44947-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Jung, K.H., Rumman, M., Yan, H., Cheon, M.J., Choi, J.G., Jin, X., et al. (2018) An Ethyl Acetate Fraction of Artemisia capillaris (ACE-63) Induced Apoptosis and Anti-Angiogenesis via Inhibition of PI3K/AKT Signaling in Hepatocellular Carcinoma. Phytotherapy Research, 32, 2034-2046. &lt;br&gt;https://doi.org/10.1002/ptr.6135</mixed-citation></ref><ref id="hanspub.44947-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Yan, H., Jung, K.H., Kim, J., Rumman, M., Oh, M.S. and Hong, S. (2018) Artemisia capillaris Extract AC68 Induces Apoptosis of Hepatocellular Carcinoma by Blocking the PI3K/AKT Pathway. Biomedicine &amp; Pharmacotherapy, 98, 134-141. &lt;br&gt;https://doi.org/10.1016/j.biopha.2017.12.043</mixed-citation></ref><ref id="hanspub.44947-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Jang, E., Kim, B.J., Lee, K.T., Inn, K.-S. and Lee, J.-H. (2015) A Survey of Therapeutic Effects of Artemisia capillaris in Liver Diseases. Evidence-Based Complementary and Alternative Medicine, 2015, Article ID: 728137.  
&lt;br&gt;https://doi.org/10.1155/2015/728137</mixed-citation></ref><ref id="hanspub.44947-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">胡泽明, 陈彪, 钟佳宁, 陈斌. 原发性肝癌治疗方法的应用进展[J]. 山东医药, 2019, 59(9): 106-110.</mixed-citation></ref><ref id="hanspub.44947-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Wang, X., Wang, N., Cheung, F., Lao, L., Li, C. and Feng, Y. (2015) Chinese Medicines for Prevention and Treatment of Human Hepatocellular Carcinoma: Current Progress on Pharmacological Actions and Mechanisms. Journal of Integrative Medicine, 13, 142-164. &lt;br&gt;https://doi.org/10.1016/S2095-4964(15)60171-6</mixed-citation></ref><ref id="hanspub.44947-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Samec, M., Liskova, A., Koklesova, L., Samuel, S.M., Zhai, K., Buhrmann, C., et al. (2020) Flavonoids against the Warburg Phenotype-Concepts of Predictive, Preventive and Personalised Medicine to Cut the Gordian Knot of Cancer Cell Metabolism. The EPMA Journal, 11, 377-398. &lt;br&gt;https://doi.org/10.1007/s13167-020-00217-y</mixed-citation></ref><ref id="hanspub.44947-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Liao, C.Y., Lee, C.C., Tsai, C.C., Hsueh, C.-W., Wang, C.-C., Chen, I-H., et al. (2015) Novel Investigations of Flavonoids as Chemopreventive Agents for Hepatocellular Carcinoma. BioMed Research International, 2015, Article ID: 840542. &lt;br&gt;https://doi.org/10.1155/2015/840542</mixed-citation></ref><ref id="hanspub.44947-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Silva, C.F.M., Batista, V.F., Pinto, D. and Silva, A.M.S. (2018) Challenges with Chromone as a Privileged Scaffold in drug Discovery. Expert Opinion on Drug Discovery, 13, 795-798. &lt;br&gt;https://doi.org/10.1080/17460441.2018.1494720</mixed-citation></ref><ref id="hanspub.44947-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">刘双利, 姜程曦, 赵岩, 许永华, 王壮, 张连学. 防风化学成分及其药理作用研究进展[J]. 中草药, 2017, 48(10): 2146-2152.</mixed-citation></ref><ref id="hanspub.44947-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Shahzad, N., Khan, W., Md, S., Ali, A., Singh Saluja, S., Sharma, S., et al. (2017) Phytosterols as a Natural Anticancer Agent: Current Status and Future Perspective. Biomedicine &amp; Pharmacotherapy, 88, 786-794.  
&lt;br&gt;https://doi.org/10.1016/j.biopha.2017.01.068</mixed-citation></ref><ref id="hanspub.44947-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Plat, J., Hendrikx, T., Bieghs, V., Jeurissen, M.L.J., Walenbergh, S.M.A., van Gorp, P.J., et al. (2014) Protective Role of Plant Sterol and Stanol Esters in Liver Inflammation: Insights from Mice and Humans. PLoS ONE, 9, e110758.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0110758</mixed-citation></ref><ref id="hanspub.44947-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Sun, X., Hu, Y., Wu, J., Shi, L., Zhu, L., Xi, P.-W., et al. (2018) RBMS2 Inhibits the Proliferation by Stabilizing P21 mRNA in Breast Cancer. Journal of Experimental &amp; Clinical Cancer Research, 37, Article No. 298.  
&lt;br&gt;https://doi.org/10.1186/s13046-018-0968-z</mixed-citation></ref><ref id="hanspub.44947-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Ehedego, H., Boekschoten, M.V., Hu, W., Doler, C., Haybaeck, J., Gaβler, N., et al. (2015) p21 Ablation in Liver Enhances DNA Damage, Cholestasis, and Carcinogenesis. Cancer Research, 75, 1144-1155.  
&lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-14-1356</mixed-citation></ref><ref id="hanspub.44947-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Diao, P.C., Lin, W.Y., Jian, X.E., Li, Y.-H., You, W.-W., Jian, X.-E., et al. (2019) Discovery of Novel Pyrimidine-Based Benzothiazole Derivatives as Potent Cyclin-Dependent Kinase 2 Inhibitors with Anticancer Activity. European Journal of Medicinal Chemistry, 179, 196-207. &lt;br&gt;https://doi.org/10.1016/j.ejmech.2019.06.055</mixed-citation></ref><ref id="hanspub.44947-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Mahajan, P., Chashoo, G., Gupta, M., Kumar, A., Pal Singh, P. and Nargotra, A. (2017) Fusion of Structure and Ligand Based Methods for Identification of Novel CDK2 Inhibitors. Journal of Chemical Information and Modeling, 57, 1957-1969. &lt;br&gt;https://doi.org/10.1021/acs.jcim.7b00293</mixed-citation></ref><ref id="hanspub.44947-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Lian, J., Zhang, X., Lu, Y., Hao, S., Zhang, Z. and Yang, Y. (2019) Expression and Significance of LncRNA-MINCR and CDK2 mRNA in Primary Hepatocellular Carcinoma. Combinatorial Chemistry &amp; High Throughput Screening, 22, 201-206. &lt;br&gt;https://doi.org/10.2174/1386207322666190404151020</mixed-citation></ref><ref id="hanspub.44947-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">朱继业, 秦致中, 王东, 栗光明, 高杰, 冷希圣, 杜如昱. 人肝癌组织中核内转录基因Fos B和Jun D的表达及其意义[J]. 中华普通外科杂志, 2001, 16(1): 14-16.</mixed-citation></ref><ref id="hanspub.44947-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">He, Y., Huang, S., Cheng, T., Wang, Y., Zhou, S.-J., Zhang, Y.-M., et al. (2020) High Glucose May Promote the Proliferation and Metastasis of Hepatocellular Carcinoma via E2F1/RRBP1 Pathway. Life Sciences, 252, Article ID: 117656. &lt;br&gt;https://doi.org/10.1016/j.lfs.2020.117656</mixed-citation></ref><ref id="hanspub.44947-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Kent, L.N., Bae, S., Tsai, S.Y., Tang, X., Srivastava, A., Koivisto, C., et al. (2017) Dosage-Dependent Copy Number Gains in E2f1 and E2f3 Drive Hepatocellular Carcinoma. The Journal of Clinical Investigation, 127, 830-842.  
&lt;br&gt;https://doi.org/10.1172/JCI87583</mixed-citation></ref><ref id="hanspub.44947-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Liu, C., Wang, C., Wang, J. and Huang, H. (2016) miR-1297 Promotes Cell Proliferation by Inhibiting RB1 in Liver Cancer. Oncology Letters, 12, 5177-5182. &lt;br&gt;https://doi.org/10.3892/ol.2016.5326</mixed-citation></ref><ref id="hanspub.44947-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Anwar, S.L., Krech, T., Hasemeier, B., Schipper, E., Schweitzer, N., Vogel, A., et al. (2014) Deregulation of RB1 Expression by Loss of Imprinting in Human Hepatocellular Carcinoma. The Journal of Pathology, 233, 392-401.  
&lt;br&gt;https://doi.org/10.1002/path.4376</mixed-citation></ref><ref id="hanspub.44947-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Jing, Y., Sun, K., Liu, W., Sheng, D., Zhao, S., Gao, L., et al. (2018) Tumor Necrosis Factor-α Promotes Hepatocellular Carcinogenesis through the Activation of Hepatic Progenitor Cells. Cancer Letters, 434, 22-32.  
&lt;br&gt;https://doi.org/10.1016/j.canlet.2018.07.001</mixed-citation></ref><ref id="hanspub.44947-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Chen, S., Tang, Y., Yang, C., Li, K., Huang, X. and Cao, J. (2020) Silencing CDC25A Inhibits the Proliferation of Liver Cancer Cells by Downregulating IL-6 in Vitro and in Vivo. International Journal of Molecular Medicine, 45, 743-752. &lt;br&gt;https://doi.org/10.3892/ijmm.2020.4461</mixed-citation></ref><ref id="hanspub.44947-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Bayard, Q., Meunier, L., Peneau, C., Renault, V., Shinde, J., Nault, J.-C., et al. (2018) Cyclin A2/E1 Activation Defines a Hepatocellular Carcinoma Subclass with a Rearrangement Signature of Replication Stress. Nature Communications, 9, Article No. 5235. &lt;br&gt;https://doi.org/10.1038/s41467-018-07552-9</mixed-citation></ref><ref id="hanspub.44947-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Gopinathan, L., Tan, S.L., Padmakumar, V.C., Coppola, V., Tessarollo, L. and Kaldis, P. (2014) Loss of Cdk2 and Cyclin A2 Impairs Cell Proliferation and Tumorigenesis. Cancer Research, 74, 3870-3879.   
&lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-13-3440</mixed-citation></ref><ref id="hanspub.44947-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Qian, H., Zhang, D. and Bao, C. (2018) Two Variants of Interleukin-1B Gene Are Associated with the Decreased Risk, Clinical Features, and Better Overall Survival of Colorectal Cancer: A Two-Center Case-Control Study. Aging, 10, 4084-4092. &lt;br&gt;https://doi.org/10.18632/aging.101695</mixed-citation></ref><ref id="hanspub.44947-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">He, B., Zhang, Y., Pan, Y., Xu, Y., Gu, L., Chen, L., et al. (2011) Interleukin 1 Beta (IL1B) Promoter Polymorphism and Cancer Risk: Evidence from 47 Published Studies. Mutagenesis, 26, 637-642.  
&lt;br&gt;https://doi.org/10.1093/mutage/ger025</mixed-citation></ref><ref id="hanspub.44947-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Yang, S., Wang, H., Qin, C., Sun, H. and Han, Y. (2020) Up-Regulation of CXCL8 Expression Is Associated with a Poor Prognosis and Enhances Tumor Cell Malignant Behaviors in Liver Cancer. Bioscience Reports, 40, Article ID: BSR20201169. &lt;br&gt;https://doi.org/10.1042/BSR20201169</mixed-citation></ref></ref-list></back></article>